Crinetics Pharmaceuticals, Inc.

CRNXNASDAQBeobachtung
US$84.85
-0.02 % today

COMPANY DATA

Sector: HealthcareIndustry: BiotechnologyCountry: USCEO: R. Scott StruthersEmployees: 594Market cap: 9 BIPO: 18/07/2018Web: www.crinetics.com

Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered,…

PRICE HISTORY

26/08/25+174.3 %26/08/26

1D

-0 %

1W

+0.2 %

1M

+1.2 %

6M

+95.5 %

YTD

+82.3 %

1Y

+174.3 %

2Y

+59.7 %

5Y

+262.3 %

10Y

–

EARNINGS

Next earnings date

05/11/2026 (in 71 days)

Volatility around earnings

~2% stronger price swings than usual

SCORES

ValuationTrendQualityDividendGrowthInsiderEarningsRevisionsSentimentShort Pressure
Valuation

Valued more expensively than its own historical average.

Why this value? Details with Pro only.

Trend

Very strong uptrend.

Why this value? Details with Pro only.

Quality

Average balance sheet quality.

Why this value? Details with Pro only.

Dividend

Not enough data yet for an assessment.

Growth

Strong expected growth at a fair price.

Why this value? Details with Pro only.

Insider

Insiders are selling more shares than they buy.

Why this value? Details with Pro only.

Earnings

Roughly meets expectations.

Why this value? Details with Pro only.

Revisions

Significantly more downgrades than upgrades from analysts recently.

Why this value? Details with Pro only.

Sentiment

Very negative social media sentiment, swinging strongly.

Why this value? Details with Pro only.

Short Pressure

Low short volume ratio.

Why this value? Details with Pro only.

Register for free

Unlock all 9 scores

  • 4 credits free on registration
  • Access to virtual portfolios and watchlist
  • No credit card, no payment details needed
  • No subscription, no minimum term
  • Our own servers in Germany, no US cloud
Create account →

Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 26/08/2026.

ASK THE AGENTS ABOUT CRNX

ANALYST ASSESSMENT

PRICE TARGET LOW

US$84.00

CONSENSUS

US$84.86

MEDIAN

US$85.00

PRICE TARGET HIGH

US$85.00

0

STRONG BUY

13

BUY

8

HOLD

0

SELL

0

STRONG SELL

21

TOTAL · Buy

DATEANALYST FIRMRATINGACTION
28/07/2026UBSBuy → Neutraldowngrade
08/07/2026Evercore ISI GroupOutperform → In Linedowngrade
08/07/2026TD CowenBuy → Holddowngrade
07/07/2026JefferiesBuy → Holddowngrade
07/07/2026OppenheimerOutperform → Performdowngrade
07/07/2026HC Wainwright & Co.Buy → Neutraldowngrade
07/07/2026Cantor FitzgeraldOverweight → Neutraldowngrade
07/07/2026BairdOutperformmaintain

METRICS

P/E

-16.8

P/B

7.51

EV/EBITDA

-17.65

RETURN ON EQUITY

-10.1 %

NET MARGIN

-481.1 %

DEBT/EQUITY

0.04

DIVIDEND YIELD

0 %

AS OF

30/06/2026

FREE FLOAT & LIQUIDITY

FREE FLOAT

93.8 %

FLOAT SHARES

99,409,534

AVG. DAILY VOLUME (30D)

2,743,702

INSIDER TRANSACTIONS (SEC)

DATEINSIDERROLETRANSACTIONSHARESPRICEPLAN TYPE
24/08/2026Schilke TobinOfficerGrant4710Spontaneous
11/08/2026Struthers Richard ScottOfficerOption exercise3,96925.19Spontaneous
11/08/2026Struthers Richard ScottOfficerOption exercise4,99520.02Spontaneous
11/08/2026Struthers Richard ScottOfficerOption exercise6,54215.29Spontaneous
11/08/2026Struthers Richard ScottOfficerOption exercise4,42222.61Spontaneous
Page 1 / 6

INSTITUTIONAL HOLDERS

FUND / INSTITUTIONSHARESCHANGEAS OF
FMR LLC15,840,219+80,42030/06/2026
BlackRock, Inc.9,758,938+1,280,12330/06/2026
FARALLON CAPITAL MANAGEMENT LLC8,989,098+651,00030/06/2026
WELLINGTON MANAGEMENT GROUP LLP7,131,084-1,026,12030/06/2026
DRIEHAUS CAPITAL MANAGEMENT LLC6,463,551+67,62930/06/2026
Page 1 / 3

Not investment advice. Past performance is not an indicator of future results.